CSIMarket
 
Io Biotech Inc   (IOBT)
Other Ticker:  
 
 
Price: $1.6500 $-0.05 -2.941%
Day's High: $1.7678 Week Perf: -3.51 %
Day's Low: $ 1.64 30 Day Perf: 2.48 %
Volume (M): 25 52 Wk High: $ 2.64
Volume (M$): $ 42 52 Wk Avg: $1.67
Open: $1.68 52 Wk Low: $0.82



 Market Capitalization (Millions $) 83
 Shares Outstanding (Millions) 50
 Employees -
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -80
 Cash Flow (TTM) (Millions $) 70
 Capital Exp. (TTM) (Millions $) 0

Io Biotech Inc
Io Biotech Inc is a biotechnology company that focuses on the development of immunotherapies for the treatment of cancer and other diseases. They aim to revolutionize the field of immunotherapy by harnessing the power of the immune system to target and eliminate cancer cells. Io Biotech Inc utilizes cutting-edge technology and innovative strategies to create personalized immunotherapeutic solutions tailored to the individual needs of patients. Through their research and development efforts, they strive to improve patient outcomes and make significant advancements in the field of cancer treatment.


   Company Address: Ole Maal?es Vej 3 Copenhagen N 0
   Company Phone Number: 7070 2980   Stock Exchange / Ticker: NASDAQ IOBT
   


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Clinical Study

IO Biotech's Phase 2 Trial Empowers the Immune System to Combat Solid Tumors

Published Thu, Dec 21 2023 1:31 PM UTC

IO Biotech Announces First Patient Dosed in Phase 2 Neoadjuvant/Adjuvant Solid Tumor Basket TrialIO Biotech, a leading biotechnology company focused on developing novel immune-oncology therapies, has recently announced the successful dosing of the first patient in their Phase 2 Neoadjuvant/Adjuvant Solid Tumor Basket Trial. This exciting development marks a major milestone f...

Io Biotech Inc

Major Pharmaceutical Prep Company Battling $-23.484M Operating Deficit, Struggling in Q3 2023



The pharmaceutical industry has been closely monitoring the financial performance of Io Biotech Inc during the third quarter of 2023. With an operating deficit of $-23.484 million and no specified revenue for the period, industry experts are analyzing the underlying factors that have contributed to these results. This article will outline the key financial facts and provide context for Io Biotech Inc's performance.
1. Operating Deficit and Revenue:
During the July to September 2023 quarter, Io Biotech Inc recorded an operating deficit of $-23.484 million. The company has not disclosed any revenue for the period. This lack of revenue has raised concerns among shareholders, who eagerly anticipate the development of a viable business model.

Io Biotech Inc

The Rising Business of IO Biotech Inc in the Major Pharmaceutical Preparations Sector: Analysis of the Fiscal Second Quarter 2023 Figures



The Major Pharmaceutical Preparations industry is known for its big players, but the market is also witnessing the emergence of lesser-known entities. IO Biotech Inc (IOBT), one such rising organization, recently announced its operating deficit for the second quarter of 2023. While the company's revenue figures have not been disclosed yet, it is important to analyze their performance in comparison to previous periods. This article aims to shed light on IOBT's financials and provide insights into this growing organization's potential.
Operating Deficit and Revenue Figures:
IOBT's operating deficit for the second quarter of 2023 stands at $-21.852 million. This loss reveals a significant decline in company performance compared to the same period in the previous year when the operating deficit was $-18.161 million. This increase in operating loss is mirrored in the net loss, which rose from $-18.495 million in the same period last year to $-21.178 million this year.

Io Biotech Inc

Io Biotech Inc. Faces Challenging Start to 2023 with Operating Shortfall of $-17.924 Million

Io Biotech Inc Reports Cumulative Net Loss and Negative ROI during Q1 2023
Io Biotech Inc,
a pharmaceutical preparations company operating within the healthcare sector, recently released its financial reports detailing the figures for the first quarter of 2023. The financial results of the company display a cumulative net loss of $-71 million over the past year, resulting in a negative return on investment (ROI) of -47.73%. Unfortunately, these numbers are not favorable when compared to the other 527 companies within the Healthcare sector.
The total ranking of the company has also deteriorated compared to the fourth quarter of 2022, falling from 0 to 3735. This indicates a weak performance of the company within the market, as its ROI is lower than most of its competitors.






 




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com